

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Francois Spertini  
SERIAL NUMBER: 10/799,514 EXAMINER : Not Yet Assigned  
FILING DATE: March 12, 2004 ART UNIT : 1644  
FOR: ALLERGEN PEPTIDE FRAGMENTS AND USE THEREOF

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (2 pages), in duplicate;
3. Copies of Cited References: A1-9; B1-5; C1-15; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.


The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 25720-502. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

*Li. Matth. Paras Reg. No. 50,572*

Ivor R. Elrifi, Reg. No. 39,529  
Attorney for Applicants  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.  
Address all written correspondence to  
Customer no.: 30623  
Tel: (617) 542-6000  
Fax: (617) 542-2241  
Customer No. 30623

Date: June 22, 2004



Express Mail Label No.: EV 392155790 US  
Date of Deposit: June 22, 2004

Attorney Docket No.: 25720-502

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT: Francois Spertini  
SERIAL NUMBER: 10/799,514 EXAMINER : Not Yet Assigned  
FILING DATE: March 12, 2004 ART UNIT : 1644  
FOR: ALLERGEN PEPTIDE FRAGMENTS AND USE THEREOF

**MAIL STOP AMENDMENT**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANT: Francois Spertini  
U.S.S.N.: 10/799,514

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.


Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 25720-502.

Respectfully submitted,

*Mr. Matthew Pava Reg No. 50,572*  
Ivor R. Elrifi, Reg. No. 39,529  
Attorney for Applicants  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.  
Address all written correspondence to  
Customer no.: 30623  
Tel: (617) 542-6000  
Fax: (617) 542-2241  
Customer No. 30623

Date: June 22, 2004

TRA 1928246v1



Express Mail No.: EV 392155790 US

Date of Deposit: June 22, 2004

Page 1 of 2

Attorney Docket No.: 25720-502

Please type a plus sign (+) in this box



Modified Form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

<b>Application Number</b>	10/799,514
<b>Filing Date</b>	03/12/04
<b>First Named Inventor</b>	Spertini
<b>Group Art Unit</b>	1644
<b>Examiner Name</b>	Not Yet Assigned
<b>Attorney Docket Number</b>	25720-502

**U.S. PATENT DOCUMENTS**

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	4,473,495	09/25/84	Patterson	260	112 R	
	A2	5,124,249	06/23/92	Khan, et al.	435	7.5	
	A3	5,152,980	10/06/92	Strom, et al.	424	85.2	
	A4	5,723,582	03/03/98	Ishizaka	530	351	
	A5	5,965,709	10/12/99	Presta, et al.	530	387.3	
	A6	6,074,673	06/13/00	Guillen	424	501	
	A7	6,395,306 B1	05/28/02	Cui, et al.	424	539	

**U.S. PUBLISHED APPLICATION DOCUMENTS**

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A8	2003/0165514 A1	09/04/03	Spertini	424	185.1	
	A9	2004/0023291 A1	02/05/04	Spertini	435	7.1	

**FOREIGN PATENT DOCUMENTS**

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1	WO 93/19178	IMMUNOLOGIC PHARMACEUTICAL CORPORATION	09/30/93	
	B2	WO 99/18983	ALK-ABELLO	04/22/99	
	B3	WO 00/15774	PAN PACIFIC PHARMACEUTICALS, INC.	03/23/00	
	B4	WO 01/88085 A2	ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE EPFL-SRI	11/22/01	
	B5	GB 2 341 389 A	PAN PACIFIC PHARMACEUTICALS, INC.	03/15/00	

**OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS**

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Akdis, et al., <i>FASEB J.</i> , 13:603-609 (1999).
	C2	Attwood, T. K., <i>Science</i> , 290(5491):471-473 (2000).
	C3	Banks, et al., in Piek T, ed., <i>Venoms of the Hyemoptera</i> , London: Academic Press, pages 329-416 (1986).
	C4	Burks, et al., <i>Eur. J. Biochem.</i> , 245:334-339 (1997).
	C5	Colman, in <i>A Structural View of Immune Recognition by Antibodies</i> , Biomolecular Research Institute, (Australia) pages 33-35.
	C6	Fasler, et al., <i>J. Allergy Clin. Immunol.</i> , 101(4 pt 1):521-530 (1998).

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C7	Jutel, et al., <i>J. Immunol.</i> , 154:41874194 (1995).
	C8	Kämmerer, et al., <i>J. Allergy Clin Immunol.</i> , 100(1):96-103 (1997).
	C9	Kämmerer, et al., <i>Clin. Exper. Allergy</i> , 27:1016-1026 (1997).
	C10	Müller, et al., <i>J. Allergy Clin. Immunol.</i> , 101:747-754 (1998).
	C11	Ngo et al., in <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Merz, et al., (ed.), Birkhäuser, Boston, MA, pp. 433 and 492-495 (1994).
	C12	Secrist, et al., <i>J. Exp. Med.</i> , 178:2123-2130 (1993).
	C13	Skolnick, et al., <i>Trends in Biotech.</i> , 18(1):34-38 (2000).
	C14	Stanley, et al., <i>Arch. Biochem. Biophys.</i> , 342(2):244-253 (1997).
	C15	Swoboda, et al., <i>J. Biol. Chem.</i> , 270(6):26072613 (1995).

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1927537v1